Objectives Here, we begin to place this vector onto a translational pathway to the clinic, by addressing some key milestones that have to be achieved.
Main results These include: (1) a single dose produces lung expression for the life-time of the mouse (approximately 2 years), (2) only brief contact time is needed to achieve transduction, (3) repeated daily administration leads to a dose-related increase in gene expression, (4) repeated monthly administration to mouse lower airways is feasible without loss of gene expression, (5) there is no evidence of chronic toxicity during a 2 year study period, (6) F/HN-SIV transduction generates persistent gene expression in human differentiated airway cultures, and human lung slices and transduces freshly obtained primary human airway epithelial cells.
Conclusions The data support F/HN-pseudotyped SIV as a promising vector for pulmonary gene therapy for a number of diseases including CF and we are now undertaking the necessary refinements to progress this vector into clinical trials.
|Number of pages||1|
|Publication status||Published - Dec 2012|
|Event||Winter Meeting of the British-Thoracic-Society 2012 - London|
Duration: 5 Dec 2012 → 7 Dec 2012